Accelmed Overview
Accelmed is a global group of funds investing in HealthTech companies (medical device, diagnostics and digital health) across all stages. It currently invests through two separate arms: Accelmed Partners a US-based lower market private equity HealthTech fund, focused on Buyout and Growth Investments in commercial HealthTech (>$10M LTM) companies; and, Accelmed Ventures an Israel based venture fund, focused on pre-commercialization and early revenue HealthTech Opportunities. Accelmed Partners is acquiring commercial HealthTech companies and fostering significant value creation by supporting management teams, driving innovation, providing growth capital and potentially integrating innovative add-on technologies, largely from Israel. Accelmed Partners targets equity investments of $10-50M per transaction. Accelmed Ventures aims to create successful medical device and digital health companies by using its deep expertise, extensive network and proven track record. It focuses on medical devices and digital health companies with exceptional leading teams; innovative solutions addressing unmet needs in major chronic disease areas such as neurodegenerative, oncology, metabolic and cardiovascular diseases; and companies with a proven clinical concept and/or a proven business model.
Latest News
growth-negative
Accelmed Announces the Acquisition of Bioventus' Advanced…
Bioventus Inc. has announced the sale of its Advanced Rehabilitation business, part of its subsidiary Bioness, to Accelmed Partners for $45 million. The transaction includes $25 million in cash at closing and up to $20 million in potential earn-out payments. Bioventus expects to net approximately $20 million after fees and expenses, which will be used to repay existing debt. This divestiture allows Bioventus to focus on its core operations and improve liquidity. The sale is expected to reduce Bioventuss annual revenue by $50 million and annual Adjusted EBITDA by $6 million. The transaction is anticipated to close in the fourth quarter of 2024, subject to customary closing conditions.
Acquisition
Accelmed Expands Senior Team With Two New Partners
growth-positive
Accelmed posts 5-fold return in NeuroPace IPO
US company NeuroPace completed an IPO on Nasdaq, raising $100 million at a post-money valuation of $500 million. Accelmed Partners had invested $15 million in NeuroPace and made a fivefold return on the investment. NeuroPace has developed a system for treating epilepsy patients and distinguishes itself with electrodes placed on the region of abnormal brain activity. The company had sales of $41.1 million in 2020. NeuroPaces share price has risen to $25.44 from its IPO price of $17.
InvestmentPublic Trading
growth-positive
Accelmed Partners closes $400m healthtech fund
Accelmed Partners, a private equity investment firm, has closed a $400 million fund for investing in US commercial stage healthtech companies. The fund was oversubscribed and backed by pension funds, insurers, family offices, and high net worth individuals. Accelmed started as a venture capital fund and has evolved into a strategic investment fund that invests larger sums in mature growth companies. The second fund focuses on medical devices, diagnostics, digital health, and technology-enabled healthcare services. It aims to capitalize on innovative sector opportunities and meet the demand for technology-enabled healthcare solutions. The closing of Fund II follows the acquisition of TearLab and leading a financing round for NeuroPace. The fund is expected to continue supporting lower middle market HealthTech companies.
Investment
growth-positive
אקסלמד משלימה רכישת אחזקות טופז בקיסטון ב-100 מיליון שקל
ExcelMed, a biomed investment fund, has completed the acquisition of the Topaz familys holdings in the Keystone Dental medical company group for 100 million shekels. This acquisition resolves a dispute between the Topaz family and ExcelMeds managing partner, Uri Geiger. ExcelMeds business model is based on acquiring US activities in the medical equipment field with limited growth and merging them with innovative activities that lack a US marketing system. ExcelMed will now own 100% of Keystones shares, which holds all the holdings in Platop.
Acquisition
Team Members
8
Web & Social Links
| Website | accelmed.com/ |
Locations
Menachem Begin Road 132, Tel Aviv-Yafo, Israel
117 Kinderkamack Rd, River Edge, NJ, USA
848 Brickell Avenue, Miami, FL, USA
Photos & Videos
No files yet
Accelmed Business
Business models
—
Product stage
—
Employees
—
Sector
—Target Customer
—Core Technology
—Tags (5)
medical-devicesbiotechnologycyber-securityhealthcarediagnosticsAccelmed Financials
—
Total funding
—
Capital raised
—
Last funding
—
Funding stage
—
Total rounds
—
Investors
Accelmed Lifecycle
Accelmed News
15 articles
growth-negative
Accelmed Announces the Acquisition of Bioventus' Advanced…
Bioventus Inc. has announced the sale of its Advanced Rehabilitation business, part of its subsidiary Bioness, to Accelmed Partners for $45 million. The transaction includes $25 million in cash at closing and up to $20 million in potential earn-out payments. Bioventus expects to net approximately $20 million after fees and expenses, which will be used to repay existing debt. This divestiture allows Bioventus to focus on its core operations and improve liquidity. The sale is expected to reduce Bioventuss annual revenue by $50 million and annual Adjusted EBITDA by $6 million. The transaction is anticipated to close in the fourth quarter of 2024, subject to customary closing conditions.
Acquisition
Accelmed Expands Senior Team With Two New Partners
growth-positive
Accelmed posts 5-fold return in NeuroPace IPO
US company NeuroPace completed an IPO on Nasdaq, raising $100 million at a post-money valuation of $500 million. Accelmed Partners had invested $15 million in NeuroPace and made a fivefold return on the investment. NeuroPace has developed a system for treating epilepsy patients and distinguishes itself with electrodes placed on the region of abnormal brain activity. The company had sales of $41.1 million in 2020. NeuroPaces share price has risen to $25.44 from its IPO price of $17.
InvestmentPublic Trading
growth-positive
Accelmed Partners closes $400m healthtech fund
Accelmed Partners, a private equity investment firm, has closed a $400 million fund for investing in US commercial stage healthtech companies. The fund was oversubscribed and backed by pension funds, insurers, family offices, and high net worth individuals. Accelmed started as a venture capital fund and has evolved into a strategic investment fund that invests larger sums in mature growth companies. The second fund focuses on medical devices, diagnostics, digital health, and technology-enabled healthcare services. It aims to capitalize on innovative sector opportunities and meet the demand for technology-enabled healthcare solutions. The closing of Fund II follows the acquisition of TearLab and leading a financing round for NeuroPace. The fund is expected to continue supporting lower middle market HealthTech companies.
Investment
growth-positive
אקסלמד משלימה רכישת אחזקות טופז בקיסטון ב-100 מיליון שקל
ExcelMed, a biomed investment fund, has completed the acquisition of the Topaz familys holdings in the Keystone Dental medical company group for 100 million shekels. This acquisition resolves a dispute between the Topaz family and ExcelMeds managing partner, Uri Geiger. ExcelMeds business model is based on acquiring US activities in the medical equipment field with limited growth and merging them with innovative activities that lack a US marketing system. ExcelMed will now own 100% of Keystones shares, which holds all the holdings in Platop.
Acquisition
growth-positive
TearLab Announces Acquisition By Accelmed Partners And Related $25 Million Investment
TearLab Corporation has entered into a definitive agreement to be acquired by Accelmed Partners II. Accelmed Partners II will invest $25 million in TearLab over two tranches. The investment will be used to pay down debt and fund organic and inorganic growth opportunities. TearLab will become a private company and Accelmed Partners II will be the controlling shareholder. The transaction is expected to close in the second quarter of 2020. TearLabs Board of Directors have unanimously approved the acquisition. Dr. Uri Geiger, Founder and Managing Partner of Accelmed Partners, will become Chairman of the Board. The transaction is subject to approval by TearLab shareholders.
InvestmentAcquisition
growth-positive
https://www.jpost.com/Jpost-Tech/Business-and-Innovation/Accelerating-interest-Everyone-is-converging-in-the-healthtech-space-614360
Accelmed Ventures II, a venture capital fund focusing on medical device and digital health companies, has announced its second deal, investing in radiotherapy medical device company BioProtect. The $13 million Series D funding round was led by the family office of Consensus Business Group chairman Vincent Tchenguiz, with participation from Korean investor KB Investment. Accelmed aims to raise a total of $100 million from investors in Israel, Europe, the United States, and Asia. The fund plans to invest an average of $10 million in eight to 12 companies and collaborate with leading hospitals and innovation centers in Israel and abroad. Israeli digital health start-ups raised $662 million in 2019, and the country has a competitive advantage in healthtech innovation due to its comprehensive data and capital efficiency.
Investment
growth-positive
Accelmed Partners Hires Head Of Abbott Ventures
Accelmed Partners, a private equity firm focused on investments in healthtech companies, has announced the appointment of Evan Norton as General Partner. Norton, a long-term veteran at Abbott Laboratories, brings extensive experience in managing investments and acquisitions in the healthtech field. Accelmed Partners, which manages four healthtech funds, is currently investing from its second private equity fund raised in 2016. The company has a successful track record of investments, including Cogentix, Keystone Dental, and Endogastric Solutions. Nortons appointment is expected to contribute to the continued growth and value creation for Accelmed Partners and its portfolio companies.
Management Changes
growth-positive
Accelmed seeks $400m for new medical devices fund
The Accelmed group of investment funds, managed by co-founding managing partner Dr. Uri Geiger, is raising a second private equity fund with $300-400 million. This fund is in addition to the raising of an Israel venture capital fund for investment in early-stage technologies. Accelmeds new fund will continue to acquire existing companies in the US and enhance them with additional technologies and involvement in management. The fund also plans to make minority investments in growing companies. Accelmed seeks companies with revenue of around $10 million and a high growth rate. The group believes that the market for small and medium-sized medical devices companies is underperforming, providing an opportunity for low-cost acquisitions.
InvestmentExpand
growth-positive
Accelmed Raises New $100 Million Fund With Vincent Tchenguiz as Cornerstone Investor
Israel-based medtech investment firm Accelmed Ventures is raising a second, $100 million fund. U.K.-based businessman Vincent Tchenguiz is a cornerstone investor in the new fund via his Consensus Business Group, and has already committed to invest $15 million in the fund. The fund aims to invest in pre-sale Israeli companies in the medtech industry that are in the process of regulatory approval and can reach an exit within five years.
Investment
growth-positive
Accelmed Launches Accelmed Ventures II, a New $100 Million Venture HealthTech Fund
Accelmed, a group of funds investing in healthtech companies, is establishing Accelmed Ventures II, a new venture capital fund with the goal of raising and managing approximately $100 million. The fund will invest in Israeli and global pre-revenue healthtech startups, including medical devices and digital health. This is the fourth fund established by the Accelmed group, which currently manages over $300 million through Accelmed Ventures and the private equity fund, Accelmed Partners. The new fund is being launched in parallel to the fruition of portfolio companies in Accelmed Ventures I.
InvestmentExpand
growth-positive
Investor Eye: Israel's Medical Device Fund Accelmed Seizes On Slow Medtech Investing
Israeli healthtech fund Accelmed is implementing a successful medtech-investment strategy, focusing on medical device companies. While VC investment in medical technology has declined, Accelmed sees opportunities in the industry. The company manages assets worth almost $300m and is looking to raise funds for a new fund this year. Accelmeds investment strategy involves integrating innovative Israeli medical device technologies into existing US companies to accelerate their growth and generate high returns. The company has completed several successful deals, including the sale of urology device maker Cogentix for $242m and the acquisition of dental implant manufacturer Keystone Dental. Accelmed also invests in targeted innovation based on disruptive technologies in large fields like diabetes and heart failure. The company believes that the trend of healthtech investment will continue to rise.
InvestmentAcquisition
growth-positive
Accelmed buys US co Keystone Dental
Accelmed, a private equity fund, has acquired full ownership of US dental implant company Keystone Dental. The US dental implant market is growing at 5-6% a year, and Keystone Dental currently has an annual revenue of $40 million. Accelmed plans to acquire an Israeli dental implant company in the value category and include its products as another brand within Keystone Dentals distribution system. The US market is experiencing consolidation, which has created challenges for Keystone Dental, but there is also growth in the dental implants market due to increased awareness and comprehensive health insurance coverage. The specific date of the event described in the article is not provided.
Acquisition
Not applicable
Accelmed Growth Partners seeks to raise $300 mln for fund PE Hub
The article is about registering for limited access to industry news, analysis, and data, as well as regular email updates.
growth-positive
Accelmed raises $115m to invest in medical devices
Accelmed, a medical devices fund, has raised $115 million for its third fund and aims to increase it to $250 million. The fund currently manages assets worth $140 million and has invested in 18 companies, with four already sold or held IPOs. The Arkin family, led by Mori Arkin, is the main investor in Accelmeds funds. Migdal Insurance and Financial Holdings Ltd. has also invested in the second and third funds. Accelmed focuses on private equity investments in mature companies with annual sales turnovers over $30 million. The fund aims to make larger deals and create significant companies based on technologies developed in Israel.
InvestmentExpand
Accelmed Team
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
Accelmed Internal
Recent Updates
Matan Eblagon
· matane@sncentral.org · Manual · 2024-11-04 11:54:10.000000
Matan Eblagon
· matane@sncentral.org · Manual · 2024-11-04 13:14:57.000000
Ortal Wein
· ortalw@sncentral.org · Automatic · 2024-12-05 16:36:12.000000
Matan Eblagon
· matane@sncentral.org · Manual · 2024-11-04 13:29:28.000000
Matan Eblagon
· matane@sncentral.org · Manual · 2024-11-04 11:54:11.000000
Matan Eblagon
· matane@sncentral.org · Manual · 2024-11-04 11:52:40.000000
Ortal Wein
· ortalw@sncentral.org · Automatic · 2024-12-05 16:37:55.000000
Matan Eblagon
· matane@sncentral.org · Manual · 2024-11-04 11:54:10.000000
Matan Eblagon
· matane@sncentral.org · Manual · 2024-11-04 13:29:27.000000
Matan Eblagon
· matane@sncentral.org · Manual · 2024-11-04 13:29:27.000000
Matan Eblagon
· matane@sncentral.org · Manual · 2024-11-04 11:54:09.000000
Matan Eblagon
· matane@sncentral.org · Manual · 2024-11-04 13:29:27.000000
Matan Eblagon
· matane@sncentral.org · Manual · 2024-11-04 11:54:11.000000
Matan Eblagon
· matane@sncentral.org · Manual · 2024-11-04 11:54:11.000000
Matan Eblagon
· matane@sncentral.org · Manual · 2024-11-04 13:14:57.000000
Matan Eblagon
· matane@sncentral.org · Manual · 2024-11-04 12:37:56.000000
Matan Eblagon
· matane@sncentral.org · Automatic · 2024-11-04 11:54:12.000000
Matan Eblagon
· matane@sncentral.org · Manual · 2024-11-04 12:40:16.000000
Matan Eblagon
· matane@sncentral.org · Manual · 2024-11-04 12:55:45.000000
Ortal Wein
· ortalw@sncentral.org · Manual · 2024-12-05 16:37:55.000000
Matan Eblagon
· matane@sncentral.org · Manual · 2024-11-04 11:54:10.000000
Matan Eblagon
· matane@sncentral.org · Manual · 2024-11-04 11:54:09.000000
Matan Eblagon
· matane@sncentral.org · Manual · 2024-11-04 11:54:10.000000
Matan Eblagon
· matane@sncentral.org · Manual · 2024-11-04 12:40:16.000000
Matan Eblagon
· matane@sncentral.org · Automatic · 2024-11-04 11:54:12.000000
Matan Eblagon
· matane@sncentral.org · Manual · 2024-11-04 11:54:10.000000
Jenny Sotnik-Talisman
· genys30@yahoo.com · Manual · 2015-12-16 19:34:19.000000
Yotam Maman
· yotamm1988@gmail.com · Manual · 2021-11-02 12:45:36.000000
Yotam Maman
· yotamm1988@gmail.com · Manual · 2021-11-02 12:46:03.000000
Yotam Maman
· yotamm1988@gmail.com · Manual · 2018-07-12 12:43:00.000000
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 56/100 |
| Missing | product stage, sector, number of employees, business model, tag line, video or image, markets, not claimed |
| BI Verification | Jenny Sotnik-Talisman |
| Registrar ID | 515293181 |
| Crunchbase | accelmed |
| Phone | +97297885599 |
| Creator | Yanina Wainscheinker |
| Creator email | yanina.wain@gmail.com |
| Last updater | Yotam Maman |
| Updater email | yotamm1988@gmail.com |
| Last update | 2020-05-18T00:00:00.000Z |
| Created | 2015-09-18T00:00:00.000Z |